BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

Conditions

• Limbal Stem Cell Deficiency (LSCD)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• BRM421 Ophthalmic Solution, 0.06% — DRUG
  Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery.

Study Details

The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests

Key Dates

Status verified

Feb 2026

Central Contacts

• Emma Iacobucci
  215-662-9393
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA